Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from EMA

European drug agency opposes Amsterdam’s erotic centre plans

EMA says relocation of sex workers to area near its HQ could bring problems associated with red light district

The Guardian - UK

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

StockNews.com

3 Stocks to Buy Now if You Think a Bull Market Is on Its Way

The early-year market rally witnessed a reversal, with inpouring macro data, the Fed’s hawkish comments, and recessionary fears. However, on the flip side, a bull market can still materialize with economic growth remaining strong. Therefore, we think quality stocks UnitedHealth Group (UNH), Johnson & Johnson (JNJ), and Salesforce (CRM) might…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

East Midlands Airport incidents and how police target them to 'disrupt criminality'

Project Servator has been designed to disrupt criminality

Nottingham Post

3 Biotech Stocks to Buy in 2023 That Could Help Set You up for Life

The biotech industry is well-positioned to witness significant growth on the backs of soaring demands and government spending. Moreover, given the sector’s defensive nature, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and United Therapeutics Corp. (UTHR) might be solid buys in 2023 that could help you set for life.…

StockNews.com

Bathurst 12 Hour: SunEnergy1 wins after dramatic late crash

The SunEnergy1 Racing Mercedes defended its Bathurst 12 Hour crown despite Jules Gounon being spun by fellow Mercedes driver Maro Engel inside the last hour.

Motorsport

EU must do more to tackle antibiotic shortages, say patient groups

The European Union's drug regulator needs to do more to tackle shortages of some widely-used antibiotics in the region, according to a letter from a group of European patient and consumer organisations reviewed by Reuters on Tuesday.

Reuters

Read news from The Economist, FT, and more,
with one subscription

100 jobs on offer as East Midlands Airport launches major recruitment drive

A variety of different roles are being advertised

Nottingham Post

Staff and pupils at Newark College excited for new aviation facilities to open

The facility is expected to open in just over a year

Nottingham Post

New warning about the risks of combining ibuprofen and codeine: a necessary step

The European Medicines Agencies (EMA) recommended European countries include new warnings on labels and in package inserts of analgesics, or pain killers, that combine codeine and ibuprofen. This recommendation was agreed at the last meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), held at the end of September 2022.

The Conversation

EU regulator recommends clearing Takeda's dengue vaccine

The European Medicines Agency is recommending that a dengue vaccine made by the Japanese pharmaceutical Takeda be authorized, in a move that could provide a new tool for millions worldwide against the potentially fatal disease

The Independent UK

Warning to anyone planning trip to Spain as Covid rules remain in place

Holidaymakers planning a half-term break need to be aware that Spain is the only EU country where travel restrictions are still in place

Wales Online

2 Stocks with Great Track Records to Buy Right Now

Despite the Fed's aggressive interest rate hikes, the job market remains strong. However, given the mounting recessionary fears, it may be prudent to invest in UnitedHealth Group (UNH) and Biogen (BIIB), based on their solid fundamentals and impressive growth prospects. Continue Reading….

StockNews.com

3 Safe Stocks You'll Want to Have Exposure to in 2022

The Fed’s aggressive monetary policies are raising recession fears. Amid such an environment, we think investors could consider adding AbbVie (ABBV), Pfizer (PFE), and Coca-Cola (KO) to their portfolios for stable returns. Read on to learn more….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Reuters

EU health regulator says COVID pandemic not over

An official at the European Union's drugs regulator said on Tuesday the COVID-19 pandemic was not over, contradicting U.S. President Joe Biden, and that a planned vaccination campaign in the region during the cold season was key to fighting it.

Reuters

Take whatever COVID booster you can get, says head of EU drugs watchdog

People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview ahead of an expected autumn rise in infections.

StockNews.com

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

Asharq Al-Awsat

EU Regulator Backs Pfizer's BA.4/5-Adapted COVID Booster

The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant. The latest recommendation is for a so-called bivalent vaccine developed by Pfizer and BioNTech, which targets BA.4/5 as well…

Get all your
news in one place.

100’s of premium titles.
One news app.

Al Jazeera

‘Completely new’ COVID strains possible in winter: EU drug agency

Existing vaccines and adaptive ones should protect people from serious illness and death, the EU agency says.

Radio France Internationale

EU regulator gives green light to omicron booster vaccines

The European Medicines Agency (EMA) has backed two separate Covid-19 booster vaccines updated to target the omicron variant of Covid-19 and developed by drugmakers Moderna and BioNTech-Pfizer.

Reuters

EU states urged to roll out COVID booster shots to fend off winter infections

EU countries should start offering COVID boosters to their populations now to contain a fresh wave of infections expected this autumn and winter, the bloc's executive said in a document seen by Reuters on Friday ahead of its official release.

Reuters

EU regulator backs use of Novavax COVID shot as a booster

The European Medicines Agency (EMA) on Thursday backed the use of Novavax's COVID-19 shot as a booster for adults, ahead of an anticipated rise in infections this winter.

Bangkok Post

EU regulator approves Omicron vaccines

The European Union’s drug regulator has recommended the use of two Omicron-tailored vaccines developed by the Pfizer-BioNTech partnership and Moderna Inc ahead of a fresh booster programme this fall across the continent.

Nottingham Post

East Midlands Airport one of top 10 most expensive to drop off passengers

'This aims to reduce the number of vehicles travelling around the busiest area of our campus'

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

1 … 3 4 5 6

People

Joe Biden

66,964 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.